Hematologic Oncology | Specialty

Treatment Landscape for Mantle Cell Lymphoma Continues to Evolve

April 16th 2014

Lymphoma expert Andre Goy, MD, provides insight into the rapidly changing treatment landscape for patients with mantle cell lymphoma.

Dr. Faderl on Chemotherapy and FLT3 Inhibitors in AML

April 11th 2014

Stefan Faderl, MD, chief, Leukemia Division, John Theurer Cancer Center, discusses combining and sequencing chemotherapy and FLT3 inhibitors for the treatment of patients with acute myeloid leukemia (AML).

Dr. Melnick on Targeting EZH2 in DLBCL

April 10th 2014

Ari Melnick, MD, a professor of medicine at the Weill Cornell Medical College, discusses EZH2 and its potential as a target in diffuse large B-cell lymphoma.

Hitting the Target: How Druker's Persistence Helped Launch a New Mode of Attack

April 10th 2014

Take a prognosis of three years, multiply it by 10, and what do you get? A staggering improvement in the survival of patients with chronic myeloid leukemia (CML), and a crucial steppingstone on the road to the targeted treatment of cancer.

Dr. Donato on Advances in the Prevention of GVHD

April 9th 2014

Michele L. Donato, MD, medical director, Blood and Marrow Collection Facility, John Theurer Cancer Center, discusses advances in the prevention of graft-versus-host disease (GVHD).

Dr. Schenkein on AG-221 for the Treatment of AML

April 8th 2014

David Schenkein, MD, Chief Executive Officer, Agios Pharmaceuticals, discusses AG-221 for the treatment of acute myeloid leukemia (AML).

Dr. Younes on the Implications of Ibrutinib's Approval for MCL

April 4th 2014

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the implications of ibrutinib's approval for patients with mantle cell lymphoma (MCL).

Targeted Therapies Usher in a New Era in CLL: Wierda Discusses Key Facets of Emerging Agents

April 4th 2014

The approval of the first small-molecule, targeted therapy for patients with chronic lymphocytic leukemia (CLL) launches a new era that promises to transform management of the disease, yet significant challenges in translating research advances into improvements in long-term outcomes remain

Dr. Erba on FLT3 Inhibitors for the Treatment of AML

April 2nd 2014

Harry Erba, MD, PhD, professor of medicine, director, Hematologic Malignancy Program, University of Alabama at Birmingham, discusses the excitement around FLT3 inhibitors for the treatment of acute myeloid leukemia (AML).

Dr. Brentjens on Challenges of CAR-Modified T Cells

March 31st 2014

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the challenges associated with CAR-modified T cells.

Younger Patients With ALL Could Bypass a Transplant

March 31st 2014

The role of allogeneic transplant in the treatment of adult patients with acute lymphoblastic leukemia (ALL) is evolving as a result of new studies providing evidence of the efficacy of an improved chemotherapy regimen

Dr. Litzow on Transplants in Patients with ALL

March 27th 2014

Mark R. Litzow, MD, chair, ECOG-ACRIN Leukemia Committee, professor of medicine, Division of Hematology, Mayo Clinic, discusses the role of transplant in patients with acute lymphoblastic leukemia

Dr. Goy on Future Agents Against Lymphoma

March 26th 2014

Andre Goy, MD, MS, chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, discusses emerging agents in lymphoma.

Obinutuzumab Gains Role in CLL Guidelines

March 25th 2014

Amid advances in targeted therapies for patients with chronic lymphocytic leukemia (CLL), researchers also have been making strides in the realm of chemoimmunotherapy regimens for the disease.

Dr. Faderl Gives an Overview of Novel Therapies for AML

March 25th 2014

Stefan Faderl, MD, chief, Leukemia Division, John Theurer Cancer Center, gives an overview of novel therapies for the treatment of patients with acute myeloid leukemia (AML).

Gilead Sciences Moves Ahead on Idelalisib Filings

March 24th 2014

Founded in 1987, Gilead Sciences made a name for itself in 1996, when it launched Vistide, a treatment for cytomegalovirus retinitis in patients with AIDS.

Dr. Ferrajoli on Individualized Treatment of CLL

March 21st 2014

Alessandra Ferrajoli, MD, associate professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses individualizing the treatment of chronic lymphocytic leukemia (CLL).

Dr. Anas Younes Discusses IPI-145 and ABT-199

March 19th 2014

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the clinical value of IPI-145 and ABT-199 as treatment options for lymphoid malignancies.

Dr. Wierda on the Treatment of Elderly CLL Patients

March 12th 2014

William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses treatment recommendations for patients with CLL.

Lymphoid Malignancy Treatment Considerations

March 11th 2014